騰盛博藥-B(02137.HK)行使選擇權 以獲Vir(VIR.US)乙肝藥物大中華區開發權
騰盛博藥-B(02137.HK)公佈,作爲與Vir(VIR.US)更廣泛合作的一部分,公司行使其選擇權,獲得VIR-3434在大中華區的獨家開發和商業化權利,以增強公司的乙型肝炎病毒(HBV)治療候選藥物臨牀管線,並作爲公司致力於開發HBV功能性治癒療法的一部分,爲探索潛在的聯合療法提供更廣泛的選擇。
根據Vir許可協議條款,在行使VIR-3434(BRII-877)的選擇權後,公司將支付相關選擇權行使費、監管和商業化等裏程碑費用,以及基於淨銷售額的分級特許權使用費,特許權使用費率介於百分之十幾到百分之二十幾之間,此類特許權使用費率或付款須進行若幹特定條件下的減免和抵扣。
VIR-3434是一種靶向HBV的廣泛中和單克隆抗體,目前處於2期臨牀開發階段。這是公司對Vir傳染性疾病項目行使的第二項選擇權,且公司仍擁有其餘下兩項選擇權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.